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BACKGROUND
Mineralocorticoid antagonists improve survival among patients with chronic, se-
vere systolic heart failure and heart failure after myocardial infarction. We evalu-
ated the effects of eplerenone in patients with chronic systolic heart failure and 
mild symptoms.
METHODS
In this randomized, double-blind trial, we randomly assigned 2737 patients with 
New York Heart Association class II heart failure and an ejection fraction of no 
more than 35% to receive eplerenone (up to 50 mg daily) or placebo, in addition to 
recommended therapy. The primary outcome was a composite of death from car-
diovascular causes or hospitalization for heart failure.
RESULTS
The trial was stopped prematurely, according to prespecified rules, after a median 
follow-up period of 21 months. The primary outcome occurred in 18.3% of patients 
in the eplerenone group as compared with 25.9% in the placebo group (hazard ra-
tio, 0.63; 95% confidence interval [CI], 0.54 to 0.74; P<0.001). A total of 12.5% of 
patients receiving eplerenone and 15.5% of those receiving placebo died (hazard 
ratio, 0.76; 95% CI, 0.62 to 0.93; P = 0.008); 10.8% and 13.5%, respectively, died of 
cardiovascular causes (hazard ratio, 0.76; 95% CI, 0.61 to 0.94; P = 0.01). Hospital-
izations for heart failure and for any cause were also reduced with eplerenone. A 
serum potassium level exceeding 5.5 mmol per liter occurred in 11.8% of patients 
in the eplerenone group and 7.2% of those in the placebo group (P<0.001).
CONCLUSIONS
Eplerenone, as compared with placebo, reduced both the risk of death and the risk 
of hospitalization among patients with systolic heart failure and mild symptoms. 
(Funded by Pfizer; ClinicalTrials.gov number, NCT00232180.)
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The activation of mineralocorti-coid receptors by aldosterone and cortisol has deleterious effects in patients with car-
diovascular disease.1 In the placebo-controlled 
Randomized Aldactone Evaluation Study (RALES),2 
adding the mineralocorticoid-receptor antagonist 
spironolactone to recommended therapy in pa-
tients with systolic heart failure and moderate-
to-severe symptoms (i.e., New York Heart Associa-
tion [NYHA] functional class III or IV symptoms) 
decreased the rate of death from any cause and 
the risk of hospitalization for cardiovascular rea-
sons. In the Eplerenone Post–Acute Myocardial In-
farction Heart Failure Efficacy and Survival Study 
(EPHESUS),3 the selective mineralocorticoid- 
receptor antagonist eplerenone, added to recom-
mended medical therapy, reduced the rates of 
death from any cause and hospitalization for car-
diovascular reasons among patients with acute 
myocardial infarction complicated by left ven-
tricular systolic dysfunction and heart failure.
Consequently, current guidelines recommend the 
use of a mineralocorticoid-receptor antagonist in 
these patients.4,5
The aim of our Eplerenone in Mild Patients 
Hospitalization and Survival Study in Heart Fail-
ure (EMPHASIS-HF) was to investigate the effects 
of eplerenone, added to evidence-based therapy, 
on clinical outcomes in patients with systolic 
heart failure and mild symptoms (i.e., NYHA 
functional class II symptoms).6
Methods
Study Oversight
The executive steering committee (see the Sup-
plementary Appendix, available with the full text 
of this article at NEJM.org) designed and oversaw 
the conduct of the trial and data analysis in col-
laboration with representatives of the study spon-
sor (Pfizer). The trial was monitored by an inde-
pendent data and safety monitoring committee. 
Data were collected, managed, and analyzed by 
the sponsor according to a predefined statistical 
analysis plan, and the analyses were replicated by 
an independent academic statistician. The manu-
script was prepared by an academic writing group, 
whose members had unrestricted access to the 
data, and was subsequently revised by all the 
authors. All the authors made the decision to sub-
mit the manuscript for publication and assume 
responsibility for the accuracy and completeness 
of the data and analyses.
Study Patients
The design of the EMPHASIS-HF trial has been 
published in detail,6 and the trial protocol and 
statistical analysis plan are available at NEJM.org. 
The trial was approved by each center’s ethics 
committee. All patients provided written informed 
consent.
Eligibility criteria were as follows: an age of 
at least 55 years, NYHA functional class II symp-
toms, an ejection fraction of no more than 30% 
(or, if >30 to 35%, a QRS duration of >130 msec 
on electrocardiography), and treatment with an 
angiotensin-converting–enzyme (ACE) inhibitor, 
an angiotensin-receptor blocker (ARB), or both 
and a beta-blocker (unless contraindicated) at the 
recommended dose or maximal tolerated dose.
Randomization was to occur within 6 months 
after hospitalization for a cardiovascular reason. 
Patients who had not been hospitalized for a car-
diovascular reason within 6 months before the 
screening visit could be enrolled if the plasma 
level of B-type natriuretic peptide (BNP) was at 
least 250 pg per milliliter or if the plasma level 
of N-terminal pro-BNP was at least 500 pg per 
milliliter in men and 750 pg per milliliter in 
women.
Key exclusion criteria were acute myocardial 
infarction, NYHA class III or IV heart failure, a 
serum potassium level exceeding 5.0 mmol per 
liter, an estimated glomerular filtration rate 
(GFR) of less than 30 ml per minute per 1.73 m2 
of body-surface area, a need for a potassium-
sparing diuretic, and any other clinically signifi-
cant, coexisting condition.
Study Procedures
We used a computerized randomization system 
involving concealed study-group assignments to 
randomly assign patients to receive eplerenone 
(Inspra, Pfizer) or matching placebo. Eplerenone 
was started at a dose of 25 mg once daily and was 
increased after 4 weeks to 50 mg once daily (or 
started at 25 mg on alternate days, and increased 
to 25 mg daily, if the estimated GFR was 30 to 
49 ml per minute per 1.73 m2), provided the se-
rum potassium level was no more than 5.0 mmol 
per liter.
Thereafter, investigators evaluated patients 
every 4 months and were instructed to decrease 
the dose of the study drug if the serum potas-
sium level was 5.5 to 5.9 mmol per liter and to 
withhold the study drug if the serum potassium 
level was 6.0 mmol per liter or more. Potassium 
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was to be remeasured within 72 hours after the 
dose reduction or study-drug withdrawal, and the 
study drug was to be restarted only if the level 
was below 5.0 mmol per liter.
Study Outcomes
The primary outcome was a composite of death 
from cardiovascular causes or a first hospital-
ization for heart failure. The prespecified adjudi-
cated secondary outcomes were hospitalization 
for heart failure or death from any cause, death 
from any cause, death from cardiovascular causes, 
hospitalization for any reason, and hospitaliza-
tion for heart failure, among others (listed in 
Table 2). Adjudication of the outcomes was car-
ried out by an independent committee (see the 
Supplementary Appendix) according to prespec-
ified criteria.
Statistical Analysis
The initial assumptions were that, with 2584 pa-
tients and an annual event rate of 18% in the 
placebo group (based on data from a subgroup 
analysis of the Candesartan in Heart Failure: As-
sessment of Reduction in Mortality and Morbid-
ity–Added trial [CHARM-Added; ClinicalTrials 
.gov number, NCT00634309]),7 our trial would 
require 813 patients with a primary outcome oc-
curring within 48 months to achieve 80% power 
to detect an 18% relative reduction in the risk of 
the primary outcome in the eplerenone group as 
compared with the placebo group (with a two-
sided alpha of 0.05). Because the overall blinded 
event rate was lower than expected, the sample 
size was increased to 3100 patients, according to 
a protocol amendment adopted in June 2009.
The data and safety monitoring committee’s 
charter specified interim analyses of the primary 
outcome after approximately 271 and 542 events 
had occurred, with a statistical stopping guide-
line for an overwhelming benefit (two-sided 
P<0.001 in favor of eplerenone). On May 6, 2010, 
after the second interim analysis, the data and 
safety monitoring committee reported to the 
executive committee chairs that the prespecified 
stopping boundary for an overwhelming benefit 
had been crossed. The full executive committee 
was informed, decided to stop the trial, and 
notified the sponsor of this decision on May 9, 
2010. Operationally, May 25, 2010, was chosen 
as the trial cutoff date for all efficacy and safety 
analyses reported here.
Comparability of baseline characteristics be-
tween the two study groups was assessed by 
means of a two-sample t-test, for continuous vari-
ables, or Fisher’s exact test, for categorical vari-
ables. The analyses of the adjudicated primary 
and secondary outcomes were conducted on data 
from all patients who had undergone randomiza-
tion, according to the intention-to-treat princi-
ple, with the use of Kaplan–Meier estimates and 
Cox proportional-hazards models. Hazard ratios, 
95% confidence intervals, and P values were cal-
culated with the use of models adjusted for the 
following prespecified baseline prognostic fac-
tors: age, estimated GFR, ejection fraction, body-
mass index, hemoglobin value, heart rate, systolic 
blood pressure, diabetes mellitus, history of hy-
pertension, previous myocardial infarction, atrial 
fibrillation, and left bundle-branch block or QRS 
duration greater than 130 msec. Sensitivity analy-
ses were also performed, by means of unadjust-
ed Cox models.
The consistency of the treatment effect was 
assessed among 20 prespecified subgroups. The 
effect in each subgroup was analyzed with the 
use of a Cox proportional-hazards model, with-
out adjustment for covariates. The treatment-by-
subgroup interaction was evaluated by means of a 
Cox proportional-hazards model with terms for 
treatment, subgroup, and their interaction.
The number of patients who would need to be 
treated to prevent one primary-outcome event 
from occurring was determined according to the 
method of Altman and Andersen.8 Post hoc com-
parisons between the two groups of the total 
number of hospitalizations for any reason and 
for heart failure were performed with the use of 
a t-test, assuming a Poisson distribution. Serious 
adverse events, anticipated adverse events, and 
adverse events leading to permanent study-drug 
withdrawal were tabulated according to random-
ized group assignment and analyzed by means 
of Fisher’s exact test.
Results
Study Patients
From March 30, 2006, through May 25, 2010, we 
recruited 2737 patients at 278 centers in 29 coun-
tries. Of these patients, 1364 were randomly as-
signed to eplerenone and 1373 to placebo. The 
two groups were balanced with respect to base-
line characteristics, and all the patients were re-
ceiving recommended pharmacologic therapy for 
systolic heart failure (Table 1).
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A total of 45 patients (3.3%) in the eplerenone 
group and 51 patients (3.7%) in the placebo 
group were enrolled on the basis of a QRS dura-
tion that was greater than 130 msec (with an 
ejection fraction >30 to 35%); 195 patients (14.3%) 
in the eplerenone group and 190 patients (13.8%) 
in the placebo group were enrolled on the basis 
of the BNP or N-terminal pro-BNP criterion (with 
no hospitalization for cardiovascular reasons 
within the 180 days before screening). Half the 
patients reported having had a myocardial in-
farction, but all cases of infarction had occurred 
more than 30 days before the screening visit.
Study-Drug Administration and Follow-Up
Eight patients (four in each study group) did not 
start the study medication and were not included 
in the safety analysis. After completion of the 
dose-adjustment phase, at 5 months, 60.2% of 
patients who had been assigned to receive eplere-
none were taking the higher dose (50 mg daily); 
the corresponding proportion in the placebo 
Table 1. Baseline Characteristics of the Patients, According to Study Group.*
Characteristic
Eplerenone 
(N = 1364)
Placebo 
(N = 1373)
Age — yr 68.7±7.7 68.6±7.6
Female sex — no. (%) 309 (22.7) 301 (21.9)
Race — no. (%)†
White 1127 (82.6) 1141 (83.1)
Black 37 (2.7) 30 (2.2)
Asian 158 (11.6) 158 (11.5)
Other 42 (3.1) 44 (3.2)
Heart rate — beats/min 72±12 72±13
Blood pressure — mm Hg
Systolic 124±17 124±17
Diastolic 75±10 75±10
Left ventricular ejection fraction — % 26.2±4.6 26.1±4.7
QRS duration — msec 121±45 122±44
QRS duration >130 msec in nonpaced baseline ECG — no./total no. (%) 298/1157 (25.8) 307/1143 (26.9)
Body-mass index‡ 27.5±4.9 27.5±4.9
Principal cause of heart failure — no. (%)
Ischemic heart disease 951 (69.7) 935 (68.1)
Nonischemic heart disease 410 (30.1) 436 (31.8)
Unknown 3 (0.2)   2 (0.1)
Duration of heart failure — yr 4.8±5.9 4.6±5.5
Medical history — no. (%)
Hospitalization for heart failure 714 (52.3) 726 (52.9)
Hypertension 910 (66.7) 909 (66.2)
Angina pectoris 590 (43.3) 599 (43.6)
Myocardial infarction 686 (50.3) 695 (50.6)
PCI 300 (22.0) 296 (21.6)
CABG 256 (18.8) 260 (18.9)
Atrial fibrillation or flutter 409 (30.0) 435 (31.7)
Left bundle-branch block in nonpaced baseline ECG 304/1171 (26.0) 318/1162 (27.4)
Diabetes mellitus 459 (33.7) 400 (29.1)
Stroke 136 (10.0) 126 (9.2)
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group was 65.3%. Among the patients taking the 
study drug at 5 months, the mean (±SD) doses in 
the eplerenone and placebo groups, respectively, 
were 39.1±13.8 mg and 40.8±12.9 mg.
At the trial cutoff date, the study drug had 
been discontinued in 222 patients (16.3%) receiv-
ing eplerenone and 228 patients (16.6%) receiving 
placebo. Among these patients, the median time 
from randomization to the last dose was 533 days 
for eplerenone and 494 days for placebo.
At the trial cutoff date, 17 patients (1.2%) in 
the eplerenone group and 15 patients (1.1%) in 
the placebo group were lost to follow-up. If con-
tact could not be made at the trial cutoff date, 
the data were censored in the analysis at the 
time of the last contact. The median duration of 
follow-up among all patients was 21 months, 
with 4783 patient-years of follow-up.
Study Outcomes
Death from cardiovascular causes or hospitaliza-
tion for heart failure (the primary outcome) oc-
curred in 249 patients (18.3%) in the eplerenone 
group and 356 patients (25.9%) in the placebo 
group (Fig. 1A and Table 2). The hazard ratio for 
the primary outcome in the eplerenone group, as 
compared with the placebo group, was 0.63 (95% 
confidence interval [CI], 0.54 to 0.74; P<0.001). The 
effect of eplerenone on this outcome was consistent 
in an unadjusted analysis (hazard ratio, 0.66; 95% 
CI, 0.56 to 0.78; P<0.001) (Table 2). It was also con-
sistent across all prespecified subgroups (Fig. 2).
Death from any cause or hospitalization for 
heart failure occurred in 270 patients (19.8%) in 
the eplerenone group as compared with 376 pa-
tients (27.4%) in the placebo group (hazard ratio, 
0.65; 95% CI, 0.55 to 0.76; P<0.001) (Table 2). A 
Table 1. (Continued.)
Characteristic
Eplerenone 
(N = 1364)
Placebo 
(N = 1373)
Hemoglobin — g/dl 13.8±1.6 13.8±1.6
Serum creatinine — mg/dl 1.14±0.30 1.16±0.31
Estimated GFR — ml/min/1.73 m2 of body-surface area 71.2±21.9 70.4±21.7
Estimated GFR rate <60 ml/min/1.73 m2 — no. (%) 439 (32.2) 473 (34.5)
Serum potassium — mmol/liter 4.3±0.4 4.3±0.4
Device therapy — no. (%)
Implantable cardioverter–defibrillator 178 (13.0) 184 (13.4)
Cardiac-resynchronization therapy 38 (2.8) 22 (1.6)
Implantable cardioverter–defibrillator with cardiac resynchronization 74 (5.4) 99 (7.2)
Medication at randomization visit — no. (%)
Diuretic 1150 (84.3) 1176 (85.7)
ACE inhibitor 1068 (78.3) 1055 (76.8)
ARB 261 (19.1) 266 (19.4)
ACE inhibitor, ARB, or both 1282 (94.0) 1275 (92.9)
Beta-blocker 1181 (86.6) 1193 (86.9)
Digitalis glycosides 363 (26.6) 377 (27.5)
Antiarrhythmic drug 196 (14.4) 192 (14.0)
Antithrombotic drug (antiplatelet or oral anticoagulant) 1205 (88.3) 1214 (88.4)
Lipid-lowering agent 857 (62.8) 856 (62.3)
* Plus–minus values are means ±SD. Percentages may not total 100 because of rounding. None of the characteristics 
 differed significantly (P<0.05) between the two groups, except for diabetes mellitus (P = 0.01) and cardiac-resynchroni-
zation therapy (P = 0.04). To convert the values for creatinine to micromoles per liter, multiply by 88.4. ACE denotes 
 angiotensin-converting enzyme, ARB angiotensin-receptor blocker, CABG coronary-artery bypass grafting, ECG electro-
cardiography, GFR glomerular filtration rate, and PCI percutaneous coronary intervention.
† Race was reported by the investigators.
‡ The body-mass index is the weight in kilograms divided by the square of the height in meters.
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total of 171 patients (12.5%) in the eplerenone 
group and 213 patients (15.5%) in the placebo 
group died (hazard ratio, 0.76; 95% CI, 0.62 to 
0.93; P = 0.008) (Fig. 1B and Table 2). A total of 
147 deaths (10.8%) in the eplerenone group and 
185 (13.5%) in the placebo group were attributed 
to cardiovascular causes (hazard ratio, 0.76; 95% 
CI, 0.61 to 0.94; P = 0.01) (Table 2).
In the eplerenone group, 408 patients (29.9%) 
were hospitalized for any reason, as compared 
with 491 (35.8%) patients in the placebo group 
(hazard ratio, 0.77; 95% CI, 0.67 to 0.88; P<0.001) 
(Fig. 1C and Table 2). Of the patients receiving 
eplerenone, 164 (12.0%) were hospitalized for 
heart failure, as compared with 253 patients 
(18.4%) receiving placebo (hazard ratio, 0.58; 
95% CI, 0.47 to 0.70; P<0.001) (Fig. 1D and Table 
2). The total number of hospitalizations (includ-
H
os
pi
ta
liz
at
io
n 
fo
r 
H
ea
rt
 F
ai
lu
re
 o
r 
D
ea
th
fr
om
 C
ar
di
ov
as
cu
la
r 
C
au
se
s 
(%
)
100
60
40
30
10
50
20
0
0 1 2 3
Years since Randomization
C
A
Hazard ratio, 0.63 (95% CI, 0.54–0.74)
P<0.001
Hazard ratio, 0.76 (95% CI, 0.62–0.93)
P=0.008
Hazard ratio, 0.77 (95% CI, 0.67–0.88)
P<0.001
Hazard ratio, 0.58 (95% CI, 0.47–0.70)
P<0.001
No. at Risk
Placebo
Eplerenone
1373
1364
848
925
512
562
199
232
Placebo
Eplerenone
H
os
pi
ta
liz
at
io
n 
fo
r 
A
ny
 R
ea
so
n 
(%
)
100
60
40
30
10
50
20
0
0 1 2 3
Years since Randomization
No. at Risk
Placebo
Eplerenone
1373
1364
742
795
403
451
146
179
Placebo
Eplerenone
D
ea
th
 fr
om
 A
ny
 C
au
se
 (%
)
100
60
40
30
10
50
20
0
0 1 2 3
Years since Randomization
D
B
No. at Risk
Placebo
Eplerenone
1373
1364
947
972
587
625
242
269
Placebo
Eplerenone
H
os
pi
ta
liz
at
io
n 
fo
r 
H
ea
rt
 F
ai
lu
re
 (%
)
100
60
40
30
10
50
20
0
0 1 2 3
Years since Randomization
No. at Risk
Placebo
Eplerenone
1373
1364
848
925
512
562
199
232
Placebo
Eplerenone
Figure 1. Cumulative Kaplan–Meier Estimates of Rates of the Primary Outcome and Other Outcomes, According to Study Group.
The hazard ratios for eplerenone versus placebo are shown for hospitalization for heart failure or death from cardiovascular causes (the 
primary outcome) (Panel A), death from any cause (Panel B), hospitalization for any reason (Panel C), and hospitalization for heart fail-
ure (Panel D).
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ing second and subsequent hospitalizations) was 
also lower in the eplerenone group (750, vs. 961 
in the placebo group, for a 24% reduction; 
P<0.001), as were the total numbers of hospital-
izations for cardiovascular reasons (509 vs. 699, 
for a 29% reduction; P<0.001) and hospitaliza-
tions for heart failure (273 vs. 429, for a 38% 
reduction; P<0.001). Findings for all other pre-
specified adjudicated secondary outcomes and 
other outcomes are summarized in Table 2, in 
which all the results are adjusted for prespeci-
fied baseline variables.
The estimated number of patients who would 
need to be treated to prevent one primary out-
come from occurring, per year of follow-up, was 
19 (95% CI, 15 to 27), and the estimated number 
needed to treat to postpone one death, per year 
of follow-up, was 51 (95% CI, 32 to 180).
Safety
During the course of the study, 188 patients 
(13.8%) receiving eplerenone and 222 patients 
(16.2%) receiving placebo discontinued the study 
drug because of an adverse event (P = 0.09). Rel-
evant adverse events are summarized in Table 3.
At 1 month, the mean change in serum cre-
atinine level from baseline was 0.15±0.35 mg per 
deciliter (13.3±30.9 µmol per liter) in the eplere-
none group, as compared with 0.07±0.29 mg per 
deciliter (6.2±25.6 µmol per liter) in the placebo 
Table 2. Primary Outcome, Component Events, and Key Secondary Outcomes.*
Outcome
Eplerenone 
(N = 1364)
Placebo 
(N = 1373)
Adjusted 
Hazard Ratio 
(95% CI)
Adjusted  
P Value
Unadjusted  
Hazard Ratio 
(95% CI)
Unadjusted 
P Value
no. of patients (%)
Primary outcome: death from cardiovascular 
causes or hospitalization for heart failure
249 (18.3) 356 (25.9) 0.63 (0.54–0.74) <0.001 0.66 (0.56–0.78) <0.001
Prespecified adjudicated secondary outcomes
Death from any cause or hospitalization for 
heart failure
270 (19.8) 376 (27.4) 0.65 (0.55–0.76) <0.001 0.68 (0.58–0.79) <0.001
Death from any cause 171 (12.5) 213 (15.5) 0.76 (0.62–0.93) 0.008 0.78 (0.64–0.95) 0.01
Death from cardiovascular causes 147 (10.8) 185 (13.5) 0.76 (0.61–0.94) 0.01 0.77 (0.62–0.96) 0.02
Hospitalization for any reason 408 (29.9) 491(35.8) 0.77 (0.67–0.88) <0.001 0.78 (0.69–0.89) <0.001
Hospitalization for heart failure 164 (12.0) 253 (18.4) 0.58 (0.47–0.70) <0.001 0.61 (0.50–0.75) <0.001
Hospitalization for cardiovascular causes 304 (22.3) 399 (29.1) 0.69 (0.60–0.81) <0.001 0.72 (0.62–0.83) <0.001
Fatal or nonfatal myocardial infarction 45 (3.3) 33 (2.4) 1.32 (0.84–2.06) 0.23 1.34 (0.86–2.10) 0.20
Death from any cause or hospitalization for 
any reason
462 (33.9) 569 (41.4) 0.75 (0.66–0.85) <0.001 0.76 (0.68–0.86) <0.001
Death from heart failure or hospitalization for 
heart failure
170 (12.5) 262 (19.1) 0.58 (0.48–0.70) <0.001 0.61 (0.51–0.74) <0.001
Fatal or nonfatal stroke 21 (1.5) 26 (1.9) 0.79 (0.44–1.41) 0.42 0.78 (0.44–1.39) 0.40
Implantation of a cardioverter–defibrillator 61 (4.5) 59 (4.3) 0.99 (0.69–1.42) 0.98 1.01 (0.71–1.45) 0.95
Implantation of a cardiac-resynchronization 
device
33 (2.4) 41 (3.0) 0.77 (0.49–1.22) 0.27 0.78 (0.49–1.23) 0.28
Hospitalization for worsening renal function† 9 (0.7) 8 (0.6) 0.97 (0.37–2.58) 0.95 1.09 (0.42–2.82) 0.86
Hospitalization for hyperkalemia† 4 (0.3) 3 (0.2) 1.15 (0.25–5.31) 0.85 1.31 (0.29–5.87) 0.72
Other outcomes‡
Sudden cardiac death 60 (4.4) 76 (5.5) 0.76 (0.54–1.07) 0.12 0.77 (0.55–1.08) 0.12
Death from worsening heart failure 45 (3.3) 61 (4.4) 0.68 (0.46–1.00) 0.05 0.71 (0.48–1.04) 0.08
* Adjusted results were adjusted for prespecified baseline characteristics (see the Statistical Analysis section). CI denotes confidence interval.
† No death was attributed to hospitalization for worsening renal function or hyperkalemia.
‡ “Other outcomes” were secondary outcomes that were adjudicated but not prespecified.
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group. At the trial cutoff date, the serum cre-
atinine level had increased from baseline by 
0.09±0.37 mg per deciliter (8.0±32.7 µmol per 
liter) and 0.04±0.40 (3.5±35.4 µmol per liter), 
respectively.
At 1 month, the mean change in potassium 
level from baseline was 0.16±0.51 mmol per liter 
in the eplerenone group, as compared with 
0.04±1.16 mmol per liter in the placebo group 
(P = 0.001). At the trial cutoff date, potassium lev-
els had increased from baseline by 0.16±0.56 and 
0.05±0.53 mmol per liter, respectively (P<0.001 
for both comparisons). A serum potassium level 
above 5.5 mmol per liter was reported in 158 of 
1336 patients (11.8%) in the eplerenone group 
and 96 of 1340 patients (7.2%) in the placebo 
group (P<0.001). A serum potassium level above 
6.0 mmol per liter occurred in 33 of 1336 patients 
(2.5%) in the eplerenone group and 25 of 1340 
patients (1.9%) in the placebo group (P = 0.29). A 
serum potassium level below 4.0 mmol per liter 
was reported in 519 of 1336 patients (38.8%) in 
the eplerenone group and 648 of 1340 patients 
(48.4%) in the placebo group (P<0.001). A serum 
potassium level below 3.5 mmol per liter was re-
ported in 100 of 1336 patients (7.5%) in the eplere-
none group and 148 of 1340 patients (11.0%) in 
the placebo group (P = 0.002).
Systolic blood pressure decreased during the 
study period to a greater degree in the eplere-
none group, with a mean overall reduction of 
2.5±17.9 mm Hg, than in the placebo group, with 
a reduction of 0.3±17.2 mm Hg (P = 0.001). There 
were no other clinically significant differences 
between the two groups with respect to labora-
tory variables, reported adverse events, or adverse 
events leading to permanent withdrawal of the 
study drug.
Discussion
We evaluated the effect of adding eplerenone to 
recommended treatment for systolic heart failure 
in patients with mild symptoms (NYHA function-
al class II symptoms). The rate of the primary 
outcome, a composite of death from cardiovas-
cular causes or hospitalization for heart failure, 
was 18.3% in the eplerenone group versus 25.9% 
in the placebo group. This effect of eplerenone 
was consistent across all prespecified subgroups. 
With eplerenone, there was also a reduction in 
both the rate of death from any cause and the 
rate of hospitalization for any reason.
The mechanisms by which mineralocorticoid-
receptor antagonists such as eplerenone provide 
cardiovascular protection in patients with heart 
failure are not completely understood. Activation 
of the mineralocorticoid receptor by both aldo-
sterone and cortisol plays an important role in 
the pathophysiology of heart failure,1,9 and min-
eralocorticoid receptors are overexpressed in the 
failing heart.10,11 Despite therapy with ACE in-
hibitors, ARBs, and beta-blockers, patients with 
even mild heart failure may have persistently 
elevated plasma aldosterone and cortisol lev-
els.12-17 Mineralocorticoid receptors are not 
blocked by these treatments.
Activation of the mineralocorticoid receptor 
has been shown to promote cardiac fibrosis in 
experimental models.18 In patients with heart 
failure,19 as well as in patients after myocardial 
infarction, the use of mineralocorticoid-receptor 
antagonists decreases extracellular-matrix turn-
over, as assessed by measuring serum levels 
of collagen biomarkers.20,21 Experimental and 
clinical studies suggest that mineralocorticoid-
receptor antagonists favorably affect several other 
important mechanisms known to have a role in 
the progression of heart failure.1,15,22,23
In our study, as anticipated, there was an in-
creased incidence of hyperkalemia among pa-
tients receiving eplerenone. This finding under-
scores the need to measure serum potassium 
levels serially and to adjust the dose of eplere-
none accordingly. We attempted to minimize 
the risk of hyperkalemia by excluding patients 
with a baseline serum potassium level above 
5.0 mmol per liter and a baseline estimated GFR 
below 30 ml per minute per 1.73 m2.
Figure 2 (facing page). Hazard Ratios for Hospitalization 
for Heart Failure or Death from Cardiovascular Causes 
(the Primary Outcome) with Eplerenone versus Placebo, 
According to Prespecified Subgroups.
The subgroups are based on baseline demographic 
and clinical characteristics. The size of the square cor-
responds to the number of patients with an event. Data 
are missing for some patients in some subgroups. ACE 
denotes angiotensin-converting enzyme, ARB angio-
tensin-receptor blocker, BNP B-type natriuretic peptide, 
CRT cardiac-resynchronization therapy, GFR glomeru-
lar filtration rate, ICD implantable cardioverter–defi-
brillator, and LVEF left ventricular ejection fraction.
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In contrast, the risk of hypokalemia was 
significantly reduced among patients receiving 
eplerenone. This is important because a serum 
potassium level below 4.0 mmol per liter has 
been associated with an increased risk of death 
from any cause among patients with systolic 
heart failure.22
Our study has some limitations. Our results 
may not be applicable to all patients with mild 
symptoms, because to be eligible for the study, 
patients had to have additional factors known 
to increase cardiovascular risk, including an age 
over 55 years, in most cases an ejection fraction 
of no more than 30%, and a recent hospitaliza-
tion for a cardiovascular reason. Use of an im-
plantable cardioverter–defibrillator was relative-
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in recent registries and trials.24,25 The early stop-
ping of the trial may have resulted in overesti-
mation of the magnitude of the treatment ef-
fect,26 but the results are consistent with those 
seen in RALES.2
In conclusion, our study showed that, as com-
pared with placebo, eplerenone added to recom-
mended therapy for systolic heart failure in pa-
tients with mild symptoms was associated with 
a reduction in the rate of death from a cardio-
vascular cause or hospitalization for heart fail-
ure. Similar reductions were seen in rates of 
death from any cause, death from cardiovascular 
causes, hospitalization for any reason, and hos-
pitalization for heart failure.
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Table 3. Selected Investigator-Reported Adverse Events and Those Leading to Permanent Withdrawal of the Study Drug, 
According to Study Group.*
Event Adverse Event
Adverse Event Leading to Study-Drug 
Withdrawal
Eplerenone 
(N = 1360)
Placebo 
(N = 1369) P Value
Eplerenone 
(N = 1360)
Placebo 
(N = 1369) P Value
no. of patients (%) no. of patients (%)
All events 979 (72.0) 1007 (73.6) 0.37 188 (13.8) 222 (16.2) 0.09
Hyperkalemia 109 (8.0) 50 (3.7) <0.001 15 (1.1) 12 (0.9) 0.57
Hypokalemia 16 (1.2) 30 (2.2) 0.05 0 3 (0.2) 0.25
Renal failure 38 (2.8) 41 (3.0) 0.82 4 (0.3) 6 (0.4) 0.75
Hypotension 46 (3.4) 37 (2.7) 0.32 0 3 (0.2) 0.25
Gynecomastia or other breast 
disorders
10 (0.7) 14 (1.0) 0.54 2 (0.1) 2 (0.1) 1.00
* Patients who had received at least one dose of the study drug were included in the safety analysis. P values were calcu-
lated on the basis of the number of patients.
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